Meagen Salinas, MD
Neurology · Englewood, CONPI 1508209875
Payments from drug & device makers
Across 208 payments — averaging $6460.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Eli Lilly$726K
- H. Lundbeck A S$351K
- Genentech, Inc.$169K
- Roche TCRC, Inc.$58K
- AbbVie$17K
- Teva Pharmaceuticals USA, Inc.$12K
- plus $11K from 16 others
What the payments were for
- Speaking & faculty fees$16,02767%
- Travel & lodging$1,8978%
- Food & beverage$5,93825%
- Education$80%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Eli Lilly | 2 | $725,949 |
| H. Lundbeck A S | 39 | $351,293 |
| Genentech, Inc. | 3 | $168,850 |
| Roche TCRC, Inc. | 6 | $57,849 |
| AbbVie | 42 | $16,935 |
| Teva Pharmaceuticals USA, Inc. | 20 | $11,746 |
| UCB SA | 2 | $5,109 |
| MDD US Operations, LLC | 20 | $2,148 |
| Boston Scientific | 11 | $1,434 |
| Acadia Pharmaceuticals Inc | 14 | $416 |
| Abbott | 7 | $404 |
| Medtronic(2 entities) | 8 | $391 |
| Neurocrine Biosciences, Inc. | 10 | $376 |
| Ipsen Biopharmaceuticals, Inc | 6 | $300 |
| Merz Pharmaceuticals, LLC | 6 | $132 |
| Acorda Therapeutics, Inc | 1 | $104 |
| Cala Health, Inc. | 4 | $80 |
| Biogen | 3 | $69 |
| Revance Therapeutics, Inc. | 1 | $51 |
| Cycle Pharmaceuticals Inc | 1 | $26 |
| Catalyst Pharmaceuticals, Inc. | 1 | $19 |
| Eisai Inc. | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,343,702 in reported general payments places this provider in the 95th percentile of 334 neurology providers in Colorado.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RytaryCarbidopa/Levodopa | 13 | $12,092 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 33 | $554 |
| Carbidopa-Levodopa ErCarbidopa/Levodopa | 21 | $410 |
| Donepezil Hcl | 15 | $43 |
Paid to pharmacies, not to this prescriber.
Other neurology in Englewood
- Rajeev KumarEnglewood$14.3M
- Marc TreihaftEnglewood$673K
- Cori MillenEnglewood$621K
- Kirsten BrachtEnglewood$151K
- Aaron HaugEnglewood$122K
- Michael PearlmanEnglewood$63K
- Enrique AlvarezAurora$14.3M
- Tamara MillerFort Collins$7.4M
- Alison AllenBasalt$4.6M
- Adam WolffDenver$2.4M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.